肝动脉化疗栓塞联合门静脉持续灌注化疗治疗原发性肝癌的临床观察  

Clinical Value About Hepatic Arterial Chemoembolization and Portal Vein Continuous Perfusion Chemotherapy in the Treatment of Primary Liver Cancer

作　　者：崔林[1] 周向荣[1] 朱扣林[1] 周兰风[1] 游芳芹[1] 陈高阳[1] 刘兴祥[1] 何学军[1] 

机构地区：[1]姜堰市人民医院肿瘤科,江苏姜堰225500

出　　处：《肿瘤基础与临床》2009年第5期409-411,共3页journal of basic and clinical oncology

摘　　要：目的探讨肝动脉化疗栓塞加门静脉持续灌注化疗治疗原发性肝癌的临床价值。方法不能手术的原发性肝癌82例,随机分成两组,观察组以TACE+PVC治疗,对照组单纯行TACE治疗,分别统计肿瘤大小、AFP、门静脉癌栓的变化以及1年生存率。结果两组治疗后总有效率:观察组57.7%(15/26),对照组30.4%(17/56),两组比较差异有统计学意义(P<0.05);治疗后AFP转阴或滴度下降二分之一以上:观察组77.8%(14/18),对照组45.0%(18/40)(P<0.05);1年生存率:观察组65.4%(17/26),对照组41.1%(23/56)(P<0.05)。结论TACE+PVC治疗原发性肝癌较单纯TACE有更高的临床有效率。Objective To investigate the clinical value about hepatic arterial chemoembolization and portal vein continuous perfusion chemotherapy in the treatment of primary liver cancer. Methods 82 cases with inoperable primary liver cancer. They were randomly divided into two groups ： observation group with the treatment of TACE ＋ PVC to TACE therapy alone as control group. Statistics were tumor size, AFP, portal vein tumor thrombus, and one year survival rate. Results The total effective rate of the two groups ： 57.7% of the observation group （15/26） , the control group 30.4% （17/56） , difference between the two groups was significant （P 〈 0.05 ） ; AFP negative after treatment, or more than one-half decline in titer, the observation group 77.8% （14/18） , the control group 45.0% （18/40） （P 〈0.05） ; 1 -year survival rate, the observation group 65.4% （17/26） , the control group 41.1% （23/56） （P 〈 0.05）. Conclusion TACE ＋ PVC treatment of primary liver cancer than TACE alone have higher clinical efficiency.

关 键 词：原发性肝癌 肝动脉化疗栓塞 门静脉持续灌注化疗 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]